Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Mid-range Performer
3136.3000 -11.00 (-0.35%)
NSE Oct 21, 2025 15:31 PM
Volume: 6,418
 

3136.30
-0.35%
Emkay
DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).
Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.
More from Dr. Lal Pathlabs Ltd.
Recommended